CAH Stock Recent News

Retirement can be daunting, but it doesn't need to be.

Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.

Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.

Lately, the market has been delivering more plot twists to investors than a season of Severance. Solid tech earnings come in tandem with pulled guidance from public-facing companies like airlines and retailers.

Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here we discuss three stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, LH and ALGN.

I present 63 high-quality dividend growth stocks for investment for May 2025, categorized by yield: High (4%+), Medium (2.5-3.9%), and Low (

Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio , May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry.